Long non-coding RNA ENST00000547547 inhibits cell proliferation, invasion and migration in colorectal cancer cells

XIAOHUI AI1,2, QINGLIANG LEI2, XIAOPING SHEN2, JIAN LI3, CHAOQUN CEN4, GANG XIE2, BO LUO2, WENSHUO ZHU2, GUI HU1, HAO WU1, MIAO CHEN1, XIAORONG LI1 and CHANGWEI LIN1

1Department of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013; 2Department of Tumor Surgery, Shaoyang Hospital of TCM, Shaoyang, Hunan 422000; Departments of 3Nuclear Medicine and 4Emergency Medicine and Intensive Care Unit, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China

Received August 25, 2017; Accepted August 10, 2018

DOI: 10.3892/or.2018.6834

Abstract. Colorectal cancer (CRC) is one of the most common and lethal types of cancer worldwide. Multiple lines of evidence have illustrated that long non-coding RNAs (lncRNAs) are critical molecules in the regulation of CRC development and progression. The identification of new lncRNAs is expected to provide new biomarkers and potential therapeutic targets for CRC diagnosis and prevention. Previous research has revealed that, ENST00000547547, a 434-bp lncRNA on human chromosome12q15 (RP11-611E13.3-001), was found to be downregulated in CRC tissues from lncRNA microarray studies. However, its role in the development and progression of CRC remains largely unknown. In the present study, we demonstrated that the ENST00000547547 level is significantly downregulated in CRC tissues compared to normal tissues. Furthermore, the overexpression of ENST00000547547 inhibited the cell proliferation, invasion and migration of CRC cells in vitro and decreased tumorigenesis ability in vivo. Furthermore, we provided the first evidence that ENST00000547547 inhibited the proliferation of CRC cells by affecting the cell cycle and apoptosis. Finally, we demonstrated that the epithelial-mesenchymal transition (EMT) process was associated with the inhibitory effects of ENST00000547547 on the invasion and migration of CRC cells. In summary, the present study indicated that lncRNA ENST00000547547 acted as a tumor suppressor in CRC, which may provide us with a new biomarker for CRC prognosis and a potential therapeutic target for molecular cancer therapy.

Introduction

Colorectal cancer (CRC) is the third most common type of cancer worldwide (1). Due to its rapid progression, invasion and metastasis, CRC is one of the leading causes of cancer-related deaths globally (2). In China, the newly diagnosed cases with CRC in 2011 were 310,244, accounting for 9.20% of the overall new cancer cases (3). Although treatment for CRC has been developed, the survival rate of CRC patients remains poor (4). Thus, a deeper understanding of the molecular and genetic networks in CRC development and progression and the identification of new molecular markers or factors are urgent.

Long non-coding RNAs (lncRNAs), generally longer than 200 nucleotides in length, are widely produced in humans and they are emerging as important regulators in a wide range of biological processes, such as proliferation, apoptosis, cell cycle arrest, cell migration and invasion (5). In recent years, lncRNAs such as ANRIL, GAS5, UCA1 and HULC were identified as functional factors in tumor initiation and progression (6-9). In human CRC, hundreds of novel lncRNAs with dysregulated expression were found by a genome-wide study and some of them demonstrated co-regulated expression patterns with their neighboring protein-coding genes, indicating that they displayed enhancer-like functions (10). In further clinical and functional studies, several lncRNAs were found to be important regulators of tumorigenesis in CRC, including PRNCR1, MALAT-1, HOTAIR and AK027294, which partly or totally affected cancer cell proliferation, metastasis, cell cycle and apoptosis. Finally, the inhibitory effects of ENST00000547547 on the invasion and migration of CRC cells were associated with the epithelial-mesenchymal transition (EMT) process. In summary, the present study indicated that lncRNA ENST00000547547 acted as a tumor suppressor in CRC, which may provide us with a new biomarker for CRC prognosis and a potential therapeutic target for molecular cancer therapy.
LncRNA ENST00000547547 is a 434-bp transcript on human chromosome 12q15 (RP11-61E13.3-001) that had a distinct expression pattern in our previous lncRNA microarray assay (15). However, the potential role of ENST00000547547 in the development and progression of CRC remains unknown. In the present study, we have assessed the expression of ENST00000547547 in CRC tissues and cells. A functional overexpression model was used to investigate its function in the proliferation, invasion and migration of CRC cells in vitro and tumorigenesis abilities in vivo. Furthermore, we investigated the potential functional mechanism of ENST00000547547 in regulating CRC cell proliferation, invasion and migration.

Materials and methods

Tissue collection. CRC tissues and adjacent non-cancerous tissues were collected from 21 patients who had undergone surgical resection of CRC at the Cancer Hospital of Hunan from January to September of 2015. The normal tissue samples were 5 cm from the edge of the tumor and were identified by a pathologist. Prior to the surgical resections, no preoperative treatment had been administered to these patients. All tissue samples were immediately frozen in liquid nitrogen after being surgically resected and then stored at -80°C until required for the analyses. Prior to sample collection, written informed consent was obtained from all patients, and all of the experiments were approved by the Research Ethics Committee of the Shangyao Hospital of TCM.

Cell lines and culture conditions. Human normal colorectal cell line NCM460 and CRC cell lines COLO320, HCT116 and LoVo were purchased from Auragenе Bioscience Co. (Changsha, China). NCM460 cells were cultured in McCoy's 5A medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). COLO320, HCT116 and LoVo cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.). All cell cultures were maintained at 37°C in humidified air with 5% CO₂. All media were supplemented with 10% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Shanghai, China).

RNA extraction and qRT-PCR analyses. Total RNA was extracted from tissues or cultured cells with TRIzol reagent (Invitrogen, Shanghai, China). For quantitative RT-PCR (qRT-PCR), cDNA was synthesized using random primers and a reverse transcription kit (Takara Biotechnology Co., Ltd., Dalian, China). qRT-PCR analyses were performed using SYBR-Green qPCR Mix (Toyobo Life Science, Osaka, Japan). All protocols were performed according to the manufacturer's instructions. The qRT-PCR assays and data collection were performed using an ABI 7300 instrument. Primers for qRT-PCR were synthesized by Invitrogen (Shanghai, China) and the sequences were as follows: ENST00000547547 sense, 5'-TTTCTAAGGCACCACT-3' and antisense, 5'-CCA AATGCTTAAAGG-3'; ZEB1 sense, 5'-AAATGGAAAC ACCAGATGC-3' and antisense, 5'-TTACACCCAGACTGC GTC-3'; Snai1 sense, 5'-GCTGTCTCCTGGTGGTT-3' and antisense, 5'-GTGACTGTACGGCTTGTCC-3'; vimentin sense, 5'-CCTGAACCTAGGGAAACTAAC-3' and antisense, 5'-GAAGTTTCTGTTGATAACCTGTC-3'; E-cadherin sense, 5'-AGGCTCTCTTCTGGCT-3' and antisense, 5'-AATAGGCTGCTTTGTCG-3'; N-cadherin sense, 5'-GCTATCATCTGCATTACC-3' and antisense, 5'-GTCTGGTTCTTCTTCTTC-3'; β-actin sense, 5'-AGGGGCCGACTGCTACT-3' and antisense, 5'-GGGCGC ACACGATGACT-3'. Thermocycling conditions were as follows: Initial DNA heat denaturation at 95°C for 3 min, followed by 39 cycles at 95°C for 10 sec and then, annealing and extending at 60°C for 30 sec in the qRT-PCR experiment. The expression levels of the target genes were normalized to the transcription level of β-actin. Each sample was analyzed in triplicate.

In situ hybridization (ISH) analysis. Paraffin-embedded sections of CRC and adjacent non-cancerous tissues were used to detect ENST00000547547 expression using the RNAscope® Assay-Brown (Advanced Cell Diagnostics, Advanced Cell Diagnostics, Inc., Newark, CA, USA) according to the manufacturer's instructions with the following modifications: Antigen retrieval for 15 min, protease digestion for 30 min at 37°C, probe incubation at 42°C overnight. The probe sequence for ENST00000547547 was 5'-GGTTTTACTCTTTCCCTCT GTTC-3'. The expression level of ENST00000547547 in the nucleus was visualized with DAB and quantitated using an automatic imaging system (Leica DMLA; Leica Microsystems, Wetzlar, Germany).

Cell transfection. For the overexpression of ENST00000547547, a pCDNA3.1-ENST00000547547 plasmid was constructed by Auragenе Bioscience Co. The plasmid carrying pCDNA3.1-ENST00000547547 (1 µg/µl) was transfected into the CRC cell lines HCT116 and LoVo using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) at a Lipofectamine 2000:pCDNA3.1-ENST00000547547 ratio of 1:2.

Cell proliferation assay. After pCDNA3.1-ENST00000547547 transfection, the transfected and control cells were seeded into 96-well plates at an initial density of 5,000 cells/well. After culture for 24, 48 and 72 h, the cells were treated with 10 µl 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (Sangon Biotech, Co., Ltd., Shanghai, China) by adding it into each well. The cells were incubated at 37°C for another 4 h, and then the medium was carefully removed and 150 µl dimethyl sulfoxide (DMSO) solution (MP Biomedicals, Santa Ana, CA, USA) was added to lyse the cells for 10 min. Finally, the absorbance was measured at 570 nm using a Multiskan MK microplate reader (Thermo Fisher Scientific, Inc., Waltham, MA, USA). All experiments were performed in triplicate.

Tumor formation assay in a nude mouse model. Six 4-week-old male BALB/c nude mice (original weight, 25 g) were obtained from the Hunan Branch of the Shanghai Laboratory Animal Center of the Chinese Academy of Sciences (Changsha, China). The mice were housed on a 12 h light/dark cycle under pathogen-free conditions and were fed an autoclaved diet ad libitum. To assess tumor formation, the mice were
subcutaneously injected with 5x10⁶/ml HCT116 cells stably expressing Lv-NC or Lv-ENST00000547547. For the tumor formation assay, the tumor volume was calculated as follows: Tumor volume = (width² x length)/2. At 28 days after the Lv-NC and Lv-ENST00000547547 inoculation, the mice were sacrificed and the tumors derived from each group were used for comparisons. The protocol was approved by the Ethics Committee on the Animal Experiments of the Third Xiangya Hospital of Central South University.

Cell migration and invasion assays. Cell migration and invasion assays were performed using Transwell chambers (micro pore size, 8 µm, 24-well; Corning®; Thermo Fisher Scientific, Inc.) without Matrigel (for migration assays) or with Matrigel (for invasion assays). Both assays were performed according to the manufacturer's instructions. Briefly, the treated cells were plated in the upper chamber at a concentration of 5x10⁴ in 500 µl FBS-free media. The bottom chamber contained 500 µl media with 10% FBS. The plates were incubated for 24 h, and then the chamber was fixed and stained with crystal violet staining solution (Beyotime Institute of Biotechnology, Haimen, China). The stained cells were imaged under a microscope at x100 magnification and the optical density (OD) values were detected using a microplate reader (Thermo Multiskan MK3; Thermo Fisher Scientific, Inc.).

Flow cytometric analysis. The CRC cell lines HCT116 and LoVo were transfected with pCDNA3.1-ENST00000547547 or pCDNA3.1-NC for 48 h and harvested. Then, the cells were washed three times with cold phosphate-buffered saline (PBS) and fixed with cold 70% ethanol overnight. For the cell cycle analysis, the cells were stained with propidium iodide (PI) (Keygentec, Inc., Nanjing, China) for 30 min at 4°C in the dark. The cell cycle profiles were assayed using flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA). For the apoptosis analysis, the cells were harvested 48 h after transfection and were stained with Annexin V-fluorescein isothiocyanate (FITC) and PI (Keygentec, Inc.) for 10 min in the dark at room temperature. The cells were then examined by flow cytometry (BD Biosciences). All of the samples were assayed in triplicate.

Western blot analysis. Cells were lysed using RIPA lysis buffer (Auragene Bioscience Co.), supplemented with a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) and phenylmethylsulfonyl fluoride (PMSF) (Auragene Bioscience Co.). Equal amounts (25 µg) of protein were loaded on a 10-12% SDS-polyacrylamide separating gel. The proteins were then transferred to a Immobilon-P polyvinylidene difluoride (PVDF) membrane (EMD Millipore, Billerica, MA, USA). The membrane was blocked with 3% bovine serum albumin-Tris-buffered saline with Tween-20 (BSA-TBST) with gentle shaking at room temperature for 90 min. Then, the membrane was probed with the indicated primary antibodies with gentle shaking at 4°C overnight. The membranes were washed with TBST (5x3 min) and incubated with specific secondary antibodies at room temperature for 1 h. A β-actin antibody (cat. no. LCA01; Auragene, Changsha, China) was used as a control and Bcl-2 (1:1,000; cat. no. AM2211; Abzoom, Changsha, China), Bax (1:500; cat. no. AM2198; Abzoom), PCNA (1:200; cat. no. AM3547; Abzoom), P21 (1:200; cat. no. B7175; Assay Biotechnology, California’s San Francisco Bay Area, CA, USA), cyclin D1 (1:1,000; cat. no. ab134175; Abcam, Dallas, TX, USA), cyclin E1 (1:100; cat. no. ab33911; Abcam), P27 (1:200; cat. no. YM0496; ImmunoWay, Changsha, China), ZEB1 (1:500; cat. no. 21544-1-AP; ProteinTech, Wuhan, China), Snai1 (1:500; cat. no. ab82846; Abcam), N-cadherin (1:1,000; cat. no. YM0465; ImmunoWay), vimentin (1:800; cat. no. BM0147; Abzoom) and E-cadherin (1:800; cat. no. BM0530; Abzoom) antibodies were used for each group. The second antibody was goat anti-rabbit IgG (H+L)-HRP (1:18,000; cat. no. SA009; Auragene Bioscience Co.) or goat anti-mouse IgG (H+L)-HRP (1:18,000; cat. no. SA001; Auragene Bioscience Co.) incubation for 1 h in room temperature.

Statistical analysis. All statistical analyses were performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA). Data are expressed as the mean ± standard deviation (SD) from at least three independent experiments. Statistical analyses were determined with Student's t-test and AVONA as appropriate. All P-values were two-sided and P<0.05 was considered to indicate a statistically significant result.

Results

ENST00000547547 is downregulated in CRC. The lncRNA microarray data revealed that lncRNA 3837 was downregulated and IncRNA 1181 was upregulated in CRC tissues. In addition, the ENST00000547547 level was decreased in the microarray data in CRC tissues compared to normal tissues (Fig. 1A). Subsequently, its expression was analyzed by qRT-PCR and in situ hybridization assays in CRC and adjacent non-cancerous tissues. The qRT-PCR results revealed that the expression of ENST00000547547 in CRC tissues was significantly decreased compared to adjacent non-tumor tissues (Fig. 1B). The in situ hybridization assay results revealed that the CRC tissues displayed lower ENST00000547547 staining than the adjacent non-cancerous tissues (Fig. 1C). The ENST00000547547 level in the human CRC cell lines COLO320, HCT116 and LoVo, and the normal human colonic epithelial cell line NCM460 was examined by qRT-PCR. As displayed in Fig. 1D, the expression of ENST00000547547 was significantly decreased in CRC cell lines compared to the expression in normal human colorectal cell lines. These results indicated that ENST00000547547 was significantly downregulated in CRC.

Overexpression of ENST00000547547 inhibits CRC cell proliferation and tumor growth. To investigate the potential biological function of ENST00000547547 in CRC cells, an ENST00000547547-overexpressing plasmid was constructed and used to transfect HCT116 and LoVo cells (16). The overexpression efficiency was verified by qRT-PCR analysis (Fig. 2A). To determine the effect of ENST00000547547 on CRC cell proliferation, an MTT assay and flow cytometric analysis were performed. The MTT results revealed that the overexpression of ENST00000547547 significantly inhibited cell proliferation in the HCT116 and LoVo cells compared to the control group (Fig. 2B). As displayed in Fig. 2C, the
overexpression of ENST00000547547 significantly increased cell apoptosis in the HCT116 and LoVo cells. Various mechanisms have been studied to explain lncRNA-mediated cell apoptosis and the most important factor identified is the activation of anti- or pro-apoptotic regulators. Bcl-2 and Bax proteins are one of the many ways to induce apoptosis (17), and proliferating cell nuclear antigen (PCNA) is known as a molecular marker for proliferation (18,19). To confirm the role of ENST00000547547-induced apoptosis, the expression levels of Bcl-2, PCNA and Bax were examined. Western blot analysis revealed that the protein levels of Bax were significantly increased in ENST00000547547-overexpressing cells, whereas the protein levels of Bcl-2 and PCNA were decreased (Fig. 2D). Collectively, these data indicated that the overexpression of ENST00000547547 could inhibit cell growth and promote apoptosis in CRC cells.

To further determine the effect of ENST00000547547 on tumorigenesis, cells stably expressing Lv-NC and Lv-ENST00000547547 were subcutaneously injected into nude mice. Nine days after the injection, a palpable tumor could be observed in both groups. There was a dramatic decrease in tumor volume in the Lv-ENST00000547547 group compared with the Lv-NC group (Fig. 2E). In addition, at 28 days, tumors derived from the Lv-ENST00000547547 group were significantly smaller than those in the control group (Fig. 2F). These results indicated that the overexpression of ENST00000547547 significantly inhibited CRC growth in vitro and in vivo.

Overexpression of ENST00000547547 induces G0/G1 phase arrest in vitro. To further assess whether the antiproliferative effects of ENST00000547547 on CRC cells were mediated by inhibiting cell cycle progression, the cell cycle was evaluated by flow cytometry and western blotting. The flow cytometric results demonstrated that overexpression of ENST00000547547 induced a significant G1-phase increase and caused an obvious reduction in the number of cells in the S phase in the HCT116 and LoVo cells (Fig. 3A and B). Furthermore, western blotting results revealed that the cell cycle-related proteins P21 and P27 were significantly increased in the ENST00000547547-overexpressing cells.
whereas the protein levels of cyclin D1 and E1 were decreased in the HCT116 and LoVo cells (Fig. 3C). These observations indicated that ENST00000547547 may induce cell cycle arrest by affecting the expression levels of cyclins. Collectively, these data demonstrated that ENST00000547547 induced G0/G1 phase arrest in CRC cells.

Overexpression of ENST00000547547 inhibits CRC cell invasion and migration in vitro. To analyze the role of ENST00000547547 in cell invasion and migration, Transwell assays were performed in HCT116 and LoVo cells and the results revealed that ENST00000547547 overexpression greatly decreased cell invasion and migration compared with the control groups (Fig. 4). These data demonstrated that the overexpression of ENST00000547547 inhibited the invasion and migration of CRC cells in vitro.

Figure 2. Effects of ENST00000547547 on CRC cell proliferation and tumor growth in vitro and in vivo. (A) The overexpression efficiency of ENST00000547547 was detected by qRT-PCR assay in the HCT116 and LoVo cells which were transfected with pCDNA3.1-ENST00000547547 or pCDNA3.1-NC for 48 h. (B) MTT assays were performed to determine the proliferation of HCT116 and LoVo cells. (C) Flow cytometry with Annexin V/PI staining was used to determine cell apoptosis in HCT116 and LoVo cells. (D) The expression of apoptosis genes (Bcl-2 and Bax) and growth gene PCNA in the HCT116 and LoVo cells was determined by western blot analysis. β-actin was used as a control. Data represent the mean ± SD from three independent experiments. (E) Tumor growth curve was based on tumor volumes (n=3) which were calculated every 7 days after injection of Lv-NC or Lv-ENST00000547547 stable cells of HCT116. (F) The tumors after removal from the mice, at 28 days; *P<0.05, **P<0.01. CRC, colorectal cancer; mock, pCDNA3.1 plasmid transfected group or Lv-NC stable cells; ENST547, pCDNA3.1-ENST00000547547 plasmid transfected group or Lv-ENST00000547547 stable cells.

Overexpression of ENST00000547547 suppresses EMT-inducing gene expression. To investigate whether the expression of ENST00000547547 regulated the progress of the epithelial-mesenchymal transition (EMT), we examined the expression levels of ZEB1, Snail, N-cadherin, vimentin and E-cadherin in ENST00000547547-overexpressing HCT116 and LoVo cells. qRT-PCR analysis indicated that overexpression of ENST00000547547 resulted in an obvious downregulation in the transcription levels of EMT-inducing genes (ZEB1, Snail1) and the biomarkers of mesenchymal cells (N-cadherin and vimentin), as well as a clear upregulation in the transcription level of E-cadherin, which is a hallmark of epithelial cells (Fig. 5A). These results were reconfirmed by western blot analysis (Fig. 5B). These data indicated that ENST00000547547 inhibited the metastasis of CRC cells by suppressing the expression of EMT-inducing genes.
Discussion

Colorectal cancer (CRC) is the third most common cancer and the fourth highest cause of cancer-related deaths worldwide, with more than 1 million individuals suffering from CRC; 694,000 people died of CRC in 2012 (20). To clarify the mechanism of CRC pathogenesis, numerous protein-coding genes and non-protein-coding genes have been shown to regulate CRC initiation and development (21,22). As non-coding transcripts, lncRNAs play critical roles in every aspect of cancer progression, such as initiation, invasion and migration, and could function as oncogenes or tumor suppressors (11,23). In CRC, lncRNAs have been identified as regulators that widely function in CRC cell proliferation, metastasis, cell cycle progression, apoptosis and EMT (12-14). In our lncRNA microarray data, we observed that lncRNA ENST00000547547, a 434-bp transcript on human chromosome12q15 (RP11-611E13.3-001), was lower in CRC tissues. In addition, it was also downregulated in adrenocortical carcinoma (ACC), pancreatic adenocarcinoma (PAAD), kidney chromophobe (KICH) and thyroid carcinoma (THCA) than in normal tissues as analyzed by the TCGA database data using GEPIA software (http://gepia.cancer-pku.cn/) (24). However, the role that ENST00000547547 plays in CRC development remained unknown.

In the present study, we provided the first evidence that ENST00000547547 was significantly downregulated in CRC tissues and human CRC cell lines. Furthermore, (23), the over-expression of ENST00000547547 significantly inhibited CRC cell proliferation in vitro and tumorigenesis in vivo. Although lncRNAs function widely in the developmental processes of various tumors, their precise regulatory mechanisms remain largely unknown. A previous study (25) revealed that the lncRNA Loc554202 decreased CRC cell proliferation by promoting significant arrest in the G0/G1 phase and CRC cell apoptosis. However, a study of the lncRNA PRNCR1

Figure 3. Effects of ENST00000547547 on colorectal cancer (CRC) cell cycle. (A and B) The percentages of HCT116 and LoVo cells in each phase were determined by flow cytometry after the upregulation of ENST00000547547. (C) The protein levels of P21, cyclin D1, cyclin E1 and P27 were determined by western blot analysis in the in vivo HCT116 and LoVo ENST00000547547-overexpressing cells. β-actin was used as a control. Data represent the mean ± SD from three independent experiments; *P<0.05. CRC, colorectal cancer; mock, pcDNA3.1 plasmid transfected group or Lv-NC stable cells; ENST547, pcDNA3.1-ENST00000547547 plasmid transfected group or Lv-ENST00000547547 stable cells.
indicated that the regulation of CRC cell proliferation was necessarily associated with affecting cell apoptosis (11). Our results revealed that the overexpression of ENST00000547547 significantly induced both cell cycle arrest in the G0/G1 phase and apoptosis in CRC cell lines. In the cell cycle progression, P21 and P27, Cip/Kip proteins, are well known for their negative role in the cell cycle (26,27). In contrast, PCNA and cyclins (cyclin D1 and E1) positively regulate the cell cycle by promoting DNA replication and pushing cells from the G1 to the S phase, respectively (28-30). Our results indicated that ENST00000547547 induced cell cycle arrest by upregulating the expression of P21 and P27 and downregulating the expression of cyclin D1 and E1. During apoptosis in tumor cells, the Bcl-2 family is critical to the regulation of apoptosis, including both death antagonists such as Bcl-2 and death agonists such as Bax (31-33). Our results demonstrated that the overexpression of ENST00000547547 decreased the expression of Bcl-2 while concomitantly, increased the expression of Bax. Along with the above-mentioned study on its effects on cell cycle, these data indicated that ENST00000547547 may be another critical effector in the regulation of the cell cycle and apoptosis in CRC cells, similar to the IncRNA Loc554202.

EMT is proposed to play a key role in the acquisition of migratory or invasive capacities by cancer cells (34,35). Previous studies indicated that decreased expression of E-cadherin and increased expression of N-cadherin and vimentin are considered to be fundamental events in EMT (36,37). Furthermore, ZEB1 and Snai1 can suppress E-cadherin directly or indirectly, and they can be considered EMT transcription factors (38). Our results indicated that the inhibition of invasion and migration in the ENST00000547547-overexpressing CRC cells was associated with the suppression of EMT-inducing genes, indicating that ENST00000547547 may be a pleiotropic suppressor participating in EMT. And the high levels of expression of any IncRNA cause stress that may serve to induce apoptosis, such as oxidative stress-induced apoptosis (39). However, the functioning role of silencing the ENST00000547547 expression level in CRC cells was not performed, and this will be the aim of our future studies. In conclusion, the present study provided the first evidence that the IncRNA ENST00000547547 was significantly downregulated in CRC tissues and cells and that its overexpression inhibited cell proliferation, migration, invasion and EMT progression, caused cell cycle arrest.
at the G1 to the S phase transition in CRC cancer cells and inhibited tumorigenesis in vivo. Collectively, our study is the first to indicate that the lncRNA ENST00000547547 acts as a tumor suppressor in CRC and that it could be a new candidate biomarker for CRC prognosis and a potential therapeutic target for molecular cancer therapy.

Acknowledgements

Not applicable.

Funding

The present study was supported by the grant from the Natural Science Foundation of Hunan Province, China (grant no. 2018JJ6073), the Hunan Provincial Health and Family Planning Commission, China (no. C20180838) and the Shaoyang Science and Technology Bureau of Hunan Province, China (no. 2017GX35).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

XA, XL and CL conceived and designed the study. XA, QL, and XS performed the experiments. JL, GH and CC performed the experiments of the in situ hybridization (ISH) analysis and wrote the paper. JL, GX, BL, MC, WZ and HW performed the experiments of the tumor formation assay in a nude mouse model, reviewed and edited the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

All experimental protocols were approved by the Shangyang Hospital of TCM (Shaoyang, China).

Patient consent for publication

Not applicable.

Competing interests

The authors state that they have no competing interests.


